Locally Advanced Rectal Cancer Clinical Trial
Official title:
A Contemporary Review of Surgical Approaches in Pelvic Exenterative Surgery
Minimally-invasive surgery (MIS) techniques have revolutionised the approach to rectal cancer surgery. With increasing experience, surgeons have began to utilise these platforms increasingly in the context of pelvic exenteration (PE). This observational retrospective review plans to assess the volume of PE being performed on a global basis and to assess the comparative outcomes associated with each technique in order to assess the optimal approach to radical pelvic surgery.
Pelvic exenteration (extended pelvic multi-visceral resection) is a radical procedure that offers potential long-term cure in appropriately selected cases of locally advanced and recurrent pelvic cancers. It was first described by Alexander Brunschwig in 1948 as a viable palliative option for advanced gynaecological cancer. However, over the last 70 years, changes in surgical oncology practices have seen its role extended to include other advanced non-gynaecological cancers (locally advanced colorectal, urological, and sarcomatous neoplasms). Although these procedures pose a significant challenge for the operating surgeon, improved surgical techniques, technology, and reconstructive options have facilitated more radical resections. Despite improved surgical options, patients still have considerable post-operative morbidity and negative impact to quality of life. However, non-surgical management options result in poor prognosis with only 3% survival at five-years. Pelvic exenteration in appropriately-selected patients offers the only hope of long-term survival. Over the last few decades with improved perioperative management and better surgical techniques, more aggressive visceral, soft tissue and bony resections are performed. The development of minimally invasive surgery (MIS) platforms has also evolved substantially, especially regarding pelvic surgery. There are some recent sporadic (low-volume) reports highlighting the potential role for MIS exenterative surgery, however many reports have been heterogeneous and single-centre. The aim of this retrospective review is to compare the volume, disease characteristics and surgical outcomes between open, laparoscopic and robotic pelvic exenterations, and to assess the initial experience of MIS platforms in multiple specialist centres worldwide. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05079438 -
Dendrobium Huoshanense Suppository in Rectal Cancer
|
Phase 3 | |
Recruiting |
NCT02964468 -
Dose-escalation Trial of Preoperative Radiotherapy and Concurrent Chemotherapy in Locally Advanced Rectal Cancer
|
N/A | |
Not yet recruiting |
NCT05507112 -
TIME in Immunotherapy Combined With nCRT for Rectal Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05998122 -
Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study
|
Phase 2 | |
Completed |
NCT04324567 -
Inflammation After Laparoscopic Robot-assisted Surgery for Locally Advanced Rectal Cancer
|
||
Recruiting |
NCT05412082 -
SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer
|
Phase 1 | |
Recruiting |
NCT05980689 -
Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal Cancer
|
Phase 2 | |
Recruiting |
NCT02605265 -
Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1
|
Phase 3 | |
Terminated |
NCT02151019 -
Pre-operative 3-DCRT vs IMRT for Locally Advanced Rectal Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05086627 -
Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05076305 -
PelvEx 4: Advanced Pelvic Malignancy and the Role of the Multi-disciplinary Team Meeting
|
||
Recruiting |
NCT03824899 -
UGT1A1 Combined With Pharmacokinetics of SN-38 in CPT-11-based CRT in Patients With Advanced Rectal Cancer
|
N/A | |
Recruiting |
NCT05845268 -
Total Neoadjuvant Therapy Combined With Tislelizumab for Local Advanced of Middle and Low Rectal Cancer
|
Phase 2 | |
Completed |
NCT03392584 -
Detection and Inflammatory Characterization of Deep Infection After Surgery for Locally Advanced Rectal Cancer With Microdialysis Catheters
|
||
Terminated |
NCT04177602 -
Evaluating Trifluridine/Tipiracil Based Chemoradiation in Locally Advanced Rectal Cancer - The Phase I/II TARC Trial
|
Phase 1/Phase 2 | |
Recruiting |
NCT05646511 -
Total Neoadjuvant Therapy of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer (ENSEMBLE)
|
Phase 3 | |
Terminated |
NCT02290574 -
Efficacy of NeoThermo-Radio-chemotherapy for LA Rectal Cancer Before Laparoscopic TME: Prospective Phase II Trial
|
N/A | |
Recruiting |
NCT03702985 -
Radiation-protection Effect of Amifostine in Locally Advanced Rectal Cancer
|
Phase 2 | |
Active, not recruiting |
NCT05877352 -
Intraoperative Electron Radiotherapy in Rectal Cancer - A Feasibility Trial
|
N/A | |
Not yet recruiting |
NCT06375434 -
Correlation Between Gut Microbiota and Radiosensitivity of Rectal Cancer
|